Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It functions as a atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. It is grouped under the following drug class(es): QTc-prolonging agents. Its therapeutic use is listed as antiarrhythmics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include vernakalantum9 and Vemakalant. Its PubChem CID is 9930049.
Vernakalant
| CAS No | 794466-70-9 |
|---|---|
| Molecular Formula | C20H31NO4 |
| Molecular Weight | 349.50 g/mol |
| Synonyms | (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It functions as a atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
The listed CAS number is 794466-70-9.
The listed molecular formula is C20H31NO4.
The listed molecular weight is 349.50 g/mol.
(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol.
The source lists vernakalantum9 and Vemakalant.